Literature DB >> 31305041

Erythema Multiforme: Recognition and Management.

Kathryn P Trayes1, Gillian Love1, James S Studdiford1.   

Abstract

Erythema multiforme is an immune-mediated reaction that involves the skin and sometimes the mucosa. Classically described as target-like, the erythema multiforme lesions can be isolated, recurrent, or persistent. Most commonly, the lesions of erythema multiforme present symmetrically on the extremities (especially on extensor surfaces) and spread centripetally. Infections, especially herpes simplex virus and Mycoplasma pneumoniae, and medications constitute most of the causes of erythema multiforme; immunizations and autoimmune diseases have also been linked to erythema multiforme. Erythema multiforme can be differentiated from urticaria by the duration of individual lesions. Erythema multiforme lesions are typically fixed for a minimum of seven days, whereas individual urticarial lesions often resolve within one day. Erythema multiforme can be confused with the more serious condition, Stevens-Johnson syndrome; however, Stevens-Johnson syndrome usually contains widespread erythematous or purpuric macules with blisters. The management of erythema multiforme involves symptomatic treatment with topical steroids or antihistamines and treating the underlying etiology, if known. Recurrent erythema multiforme associated with the herpes simplex virus should be treated with prophylactic antiviral therapy. Severe mucosal erythema multiforme can require hospitalization for intravenous fluids and repletion of electrolytes.

Entities:  

Year:  2019        PMID: 31305041

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  18 in total

1.  Erythema multiforme major associated with Mycoplasma pneumoniae infection.

Authors:  Jason T Bau; Curtis L Cooper
Journal:  CMAJ       Date:  2019-10-28       Impact factor: 8.262

2.  Erythema Multiforme Following Hepatitis A and Pneumococcal Vaccinations.

Authors:  Eli Hernandez Quiroz; Catharine Lisa Kauffman; Agnieszka Kupiec-Banasikowska
Journal:  Yale J Biol Med       Date:  2022-06-30

3.  Drug-induced Erythema Multiforme Major in an Elderly Female.

Authors:  Roshniben Patel; Akhila Mohan; Noha Omar; Maria Pardi
Journal:  J Community Hosp Intern Med Perspect       Date:  2022-05-02

4.  Role of CD123 (+) Plasmacytoid Dendritic Cells in Etiologically Different Variants of Erythema Multiforme: A Monocentric Retrospective Study.

Authors:  Hatice B Zengin; Tatsiana Pukhalskaya; Bruce R Smoller
Journal:  Dermatopathology (Basel)       Date:  2021-04-03

5.  Simultaneous Development of Gianotti-Crosti Syndrome and Erythema Multiforme Following Second Dose of Measles-rubella Vaccine.

Authors:  Masahiro Oka
Journal:  Acta Derm Venereol       Date:  2021-04-26       Impact factor: 3.875

6.  A flare of pre-existing erythema multiforme following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine.

Authors:  M J Lavery; S Nawimana; R Parslew; L Stewart
Journal:  Clin Exp Dermatol       Date:  2021-05-25       Impact factor: 4.481

Review 7.  Systemic and organ-specific immune-related manifestations of COVID-19.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Xavier Mariette
Journal:  Nat Rev Rheumatol       Date:  2021-04-26       Impact factor: 20.543

8.  Sporotrichosis: hyperendemic by zoonotic transmission, with atypical presentations, hypersensitivity reactions and greater severity.

Authors:  Regina Casz Schechtman; Eduardo Mastrangelo Marinho Falcão; Marciela Carard; Maria Salomé Cajas García; Diana Stohmann Mercado; Roderick James Hay
Journal:  An Bras Dermatol       Date:  2021-12-08       Impact factor: 1.896

9.  A fatal case of COVID-19 infection presenting with an erythema multiforme-like eruption and fever.

Authors:  Luigi Gargiulo; Giulia Pavia; Paola Facheris; Mario Valenti; Francesco Sacrini; Alessandra Narcisi; Riccardo Borroni; Antonio Costanzo; Luca Livio Mancini
Journal:  Dermatol Ther       Date:  2020-07-01       Impact factor: 3.858

10.  Oral vesiculobullous lesions associated with SARS-CoV-2 infection.

Authors:  Carmen Martín Carreras-Presas; Juan Amaro Sánchez; Antonio Francisco López-Sánchez; Enric Jané-Salas; Maria Luisa Somacarrera Pérez
Journal:  Oral Dis       Date:  2020-05-29       Impact factor: 4.068

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.